More about Torrent Pharmaceuticals Limited
Fundamentals for Torrent Pharmaceuticals Limited
Regulatory Filings for Torrent Pharmaceuticals Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Torrent Pharmaceuticals Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Revenue projections:
Torrent Pharmaceuticals Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 1.396000 |
|---|---|
| forwardPE | 41.999935 |
| debtToEquity | 33.400000 |
| earningsGrowth | 0.305000 |
| revenueGrowth | 0.143000 |
| grossMargins | 0.756870 |
| operatingMargins | 0.266200 |
| trailingEps | 63.290000 |
| forwardEps | 0.000000 |
A current ratio of 1.396 for TORNTPHARM implies that the company has ample liquidity to meet its short-term debts. TORNTPHARM's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
TORNTPHARM's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with TORNTPHARM expected to increase its market presence and profitability.
Torrent Pharmaceuticals Limited's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
Price projections:
Over time, price projections for TORNTPHARM have been gradually revised upward, reflecting increasing optimism about the company's future performance. This trend suggests analysts are growing more confident in TORNTPHARM's ability to deliver strong results and achieve higher market value.
Recommendation changes over time:
TORNTPHARM has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see TORNTPHARM as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape